English  |  正體中文  |  简体中文  |  Items with full text/Total items : 6047/14565 (42%)
Visitors : 13677962      Online Users : 369
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.fy.edu.tw:8080/ir/handle/987654321/4079

    Title: Intravesical Instillation of Taipei-NIPM Bacillus Calmette-Guerin in Prophylactic Treatment of Superficial Bladder Cancer: A Preliminary Report of Phase I-II Clinical Trial
    Authors: Chang,Sun-Yran;Yu,Dah-Shyong;Yen,Chung-Yang;Yang,Tai-Hou;Su,Chung-Jen;Cheng,Chen-Li;Wang,Hsia-Hsien;Ma,Cheng-Ping;Liau,Ming-I
    Contributors: 輔英科技大學 生物科技系
    Keywords: Taipei-NIPM BCG;intravesical instillation;superficial bladder cancer
    Date: 1990-03
    Issue Date: 2010-10-11 13:51:07 (UTC+8)
    Abstract: A domestically produced bacillus Calmette-Guerin (named), derived from Tokyo-172 strain, was used to treat 11 patients (M: F=7: 4) with superficial bladder cancer (10 stage A and 1 stage B2; 2 grade I, 8 grade II, and 1 grade III). The phase I-II clinical trial was performed to assess the side effects and efficacy of BCG as a prophylaxis againt recurrence. BCG, 50 mg in 50 ml distilled water, was instilled intravesically without cutaneous inoculation. Instillations were given weekly for 6 consecutive weeks. Hematology and biochemistry, including hepatic and renal function, were monitored. Only minor toxicity and/or side effects were observed during therapy and for a period of 5 to 12 months after treatment. Complications included cystitis in 55 per cent of the patients, hematuria in 27 per cent, fever in 9 per cent, and a flu-like syndrome in 9 per cent. A progressive decrease of white blood cell count (55%), hemoglobin (73%), and an increase in the lymphocytic ratio in peripheral white cells (82%) were noticed. Of the patients, 64 per cent had no tumor recurrence 5 to 12 months (mean 8.7 months) after therapy. These preliminary results suggest that intravesical Taipei-NIPM strian BCG instillation is effective as a prophylaxis against recurrent superficial bladder tumors.
    Relation: 中華民國泌尿科醫學會雜誌,1卷1期, 頁17-23
    Journal of the Urological Association of R.O.C.,1(1): 17-23
    Appears in Collections:[生物科技系] 期刊論文

    Files in This Item:

    File Description SizeFormat

    All items in FYIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback